VALID, a Techbio startup dedicated to reshaping drug discovery with complex human induced pluripotent stem cell (iPSC) co-culture models that deliver increased predictive validity, has partnered with ...
Valid (BVMF:VLID3) presented its fourth-quarter and full-year 2025 results on March 19, 2026, showcasing a company in transition as its digital business surged while traditional payment card ...
NATICK, MASSACHUSETTS / ACCESS Newswire / January 22, 2025 / VALID, a Techbio startup dedicated to reshaping drug discovery with complex human induced pluripotent stem cell (iPSC) co-culture models ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results